Cargando…

Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells

SIMPLE SUMMARY: Immunotherapy is designed to stimulate the patient’s own immune system to fight their specific cancer. While immune checkpoint therapies work well for some tumors, they fail to work in tumors that are “immune cold”. Oncolytic viruses are viruses that preferentially target tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davola, Maria Eugenia, Cormier, Olga, Vito, Alyssa, El-Sayes, Nader, Collins, Susan, Salem, Omar, Revill, Spencer, Ask, Kjetil, Wan, Yonghong, Mossman, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953776/ https://www.ncbi.nlm.nih.gov/pubmed/36831636 http://dx.doi.org/10.3390/cancers15041295

Ejemplares similares

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
por: El-Sayes, Nader, et al.
Publicado: (2022)

Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma
por: Cuddington, Breanne P, et al.
Publicado: (2015)

Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
por: Davola, Maria Eugenia, et al.
Publicado: (2019)

Hypoxia-Driven Immune Escape in the Tumor Microenvironment
por: Vito, Alyssa, et al.
Publicado: (2020)

Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
por: El-Sayes, Nader, et al.
Publicado: (2021)

Epidemiology and genetic characterization of BVDV, BHV-1, BHV-4, BHV-5 and Brucella spp. infections in cattle in Turkey
por: ASLAN, Muhammet Eren, et al.
Publicado: (2015)

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

BHV1 infections: Relevance and spread in Europe
por: Straub, Otto Christian
Publicado: (1991)

Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
por: Farrukh, Hadia, et al.
Publicado: (2021)

BVDV and BHV-1 Infections in Dairy Herds in Northern and Northeastern Thailand
por: Kampa, J, et al.
Publicado: (2004)

The Antiapoptotic Effect of BHV-1 in Sorbitol-induced Apoptosis in MDBK Cells
por: Marfè, G., et al.
Publicado: (2001)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma
por: Brandetti, Elisa, et al.
Publicado: (2017)

BHV-1 induced oxidative stress contributes to mitochondrial dysfunction in MDBK cells
por: Zhu, Liqian, et al.
Publicado: (2016)

Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1
por: Khattar, Sunil K., et al.
Publicado: (2010)

Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme
por: Burton, Chase, et al.
Publicado: (2018)

Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions
por: Liu, Junfeng, et al.
Publicado: (2023)

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013)

Induction of humoral responses to BHV-1 glycoprotein D expressed by HSV-1 amplicon vectors
por: Blanc, Andrea Maria, et al.
Publicado: (2012)

Pathogenic mechanisms implicated in the intravascular coagulation in the lungs of BVDV-infected calves challenged with BHV-1
por: Risalde, María A, et al.
Publicado: (2013)

To dampen demyelination
por: Maxmen, Amy
Publicado: (2010)

Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING
por: Heath, Blake R., et al.
Publicado: (2023)

Association of herd BRSV and BHV-1 seroprevalence with respiratory disease and reproductive performance in adult dairy cattle
por: Raaperi, Kerli, et al.
Publicado: (2012)

A quantitative enzyme-linked immunosorbent assay for bovine herpesvirus type 1 (BHV-1) antibody
por: Lyaku, J.R.S., et al.
Publicado: (1990)

DeepBhvTracking: A Novel Behavior Tracking Method for Laboratory Animals Based on Deep Learning
por: Sun, Guanglong, et al.
Publicado: (2021)

Exploration of semen quality analyzed by casa-mot systems of brahman bulls infected with BLV and BHV-1
por: Pichardo-Matamoros, Derling, et al.
Publicado: (2023)

Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer
por: Ingemarsdotter, C K, et al.
Publicado: (2010)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms
por: Kim, Dae-Sun, et al.
Publicado: (2017)

Effects of 3 Different Commercial Vaccines Formulations against BVDV and BHV-1 on the Inflammatory Response of Holstein Heifers
por: Costa Baccili, Camila, et al.
Publicado: (2019)

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors
por: Workenhe, Samuel T., et al.
Publicado: (2020)

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
por: Zhang, Yalei, et al.
Publicado: (2021)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment
por: DePeaux, Kristin, et al.
Publicado: (2023)

Course of disease in multifocal choroiditis lacking sufficient immunosuppression: a case report
por: Schroeder, Katharina, et al.
Publicado: (2016)

BHV4 (bovine herpes virus 4) related disorders in Belgian cattle: A study of two problem herds
por: van Opdenbosch, E., et al.
Publicado: (1988)

Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies
por: Fergusson, Dean A., et al.
Publicado: (2019)

Splenic schooling dampens inflammation
por: Van Epps, Heather L.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_c70bn28loockmskge62a2o9f6j